PUBLISHER: DelveInsight | PRODUCT CODE: 1173639
PUBLISHER: DelveInsight | PRODUCT CODE: 1173639
Complex Regional Pain Syndrome (CRPS) - Epidemiology Forecast - 2032
DelveInsight's " Complex Regional Pain Syndrome (CRPS)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2019-2032.
Complex Regional Pain Syndrome (CRPS) Understanding
The DelveInsight's Complex Regional Pain Syndrome epidemiology report gives a thorough understanding of the CRPS, which is a broad term describing excess and prolonged pain and inflammation that follows an injury to an arm or leg or any part of the body. CRPS is clinically characterized by sensory, autonomic, and motor disturbances; it can affect any part of the body, but occurs most often in the extremities. The wrist is most frequently affected after distal radial fractures. Complex regional pain syndrome can develop after different types of injuries, such as sprains and strains, surgeries, fractures, contusions, nerve lesions, stroke, etc.
CRPS has acute (recent, short-term) and chronic (lasting greater than six months) forms. Besides the increased perception of pain, other signs and symptoms that are seen with CRPS, particularly in its early stages are a warm, red, and swollen extremity on the affected side. There are two types of CRPS, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury. Although the triggers vary, both types of CRPS have the same symptoms and go through the same three stages of the disease. CRPS used to be known as reflex sympathetic dystrophy (RSD) (Type I) and causalgia (Type II). Type I comprises about 90 percent of all cases of CRPS.
There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.
Complex Regional Pain Syndrome (CRPS) Epidemiology
The epidemiology section provides insights about the historical and current CRPS patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted CRPS epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
In 2021, the total prevalent case of CRPS was ~318,500 cases in the 7MM, which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total Prevalent Cases of CRPS, Total Diagnosed Prevalent Cases of CRPS, Gender-specific Diagnosed Prevalent Cases of CRPS, Age-specific Diagnosed Prevalent Cases of CRPS, Type-specific Diagnosed Prevalent Cases of CRPS, Severity-Specific Diagnosed Prevalent Cases of CRPS, and Total treated cases of CRPS] in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
Country Wise- Complex Regional Pain Syndrome (CRPS) Epidemiology
The epidemiology segment also provides the CRPS epidemiology data and findings across the United States, EU4 and the United Kingdom, and Japan.
KOL- Views
To keep up with the current CRPS patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the CRPS domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report:
- The report covers the descriptive overview of CRPS, explaining its causes, symptoms, and pathophysiology.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries and the United Kingdom, and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of CRPS.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of CRPS, Total Diagnosed Prevalent Cases of CRPS, Gender-specific Diagnosed Prevalent Cases of CRPS, Age-specific Diagnosed Prevalent Cases of CRPS, Type-specific Diagnosed Prevalent Cases of CRPS, Severity-Specific Diagnosed Prevalent Cases of CRPS, and Total treated cases of CRPS in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032
Report Highlights:
- The companies and academics are working to assess challenges and seek opportunities that could influence CRPS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CRPS.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Complex Regional Pain Syndrome (CRPS) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- CRPS Epidemiology Segmentation
Key Questions
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of CRPS?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
- What is the historical CRPS patient pool in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
- What would be the forecasted patient pool of CRPS in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about CRPS?
- Out of all 7MM countries, which country would have the highest prevalent population of CRPS during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the CRPS Disease market
- To understand the future market competition in the CRPS Disease market
- Organize sales and marketing efforts by identifying the best opportunities for CRPS Disease in the US, the EU4 and the UK, and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the CRPS Disease market
- To understand the future market competition in the CRPS Disease market
Table of Contents
1. Key Insights
2. Report Introduction
3. Complex Regional Pain Syndrome (CRPS) Market Overview at a Glance: By Class
- 3.1. Market Share (%) Distribution of CRPS in 2019
- 3.2. Market Share (%) Distribution of CRPS in 2032
4. Executive Summary of CRPS
- 4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Classification
- 6.3. Signs and Symptoms
- 6.4. Clinical Manifestations
- 6.5. Natural Course
- 6.5.1. Stages
- 6.6. Pathophysiology
7. Diagnosis of CRPS
- 7.1. Investigations
- 7.1.1. IASP Diagnostic Criteria
- 7.2. Imaging Techniques
- 7.3. Non-invasive imaging techniques
- 7.4. Thermography
- 7.5. Sudomotor Function Tests
- 7.6. Neurophysiological Tests
- 7.7. Examination
- 7.8. Differential diagnosis
- 7.9. Diagnostic Guidelines for CRPS
- 7.9.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition, 2022
- 7.9.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
- 7.9.3. Japanese CRPS diagnostic criteria
8. Treatment and Management of CRPS
- 8.1. Treatment Guidelines
- 8.1.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition - the USA
- 8.1.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale
- 9.3. Epidemiology Scenario: 7MM
- 9.3.1. Total Prevalent Cases of CRPS in the 7MM
- 9.3.2. Total Diagnosed Prevalent cases of CRPS in the 7MM
- 9.3.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM
- 9.3.4. Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM
- 9.3.5. Type-specific Diagnosed Prevalent Cases of CRPS in the 7MM
- 9.3.6. Severity-specific Diagnosed Prevalent Cases of CRPS in the 7MM
- 9.3.7. Treated cases of CRPS in the 7MM
- 9.4. The United States Epidemiology
- 9.4.1. Total Prevalent Cases of CRPS in the United States
- 9.4.2. Total Diagnosed Prevalent cases of CRPS in the United States
- 9.4.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United States
- 9.4.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United States
- 9.4.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United States
- 9.4.6. Severity-specific Diagnosed Prevalent Cases of CRPS in the United States
- 9.4.7. Treated cases of CRPS in the US
- 9.5. EU4 and the UK Epidemiology
- 9.5.1. Total Prevalent Cases of CRPS in EU4 and the UK
- 9.5.2. Total Diagnosed Prevalent cases of CRPS in EU4 and the UK
- 9.5.3. Gender-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
- 9.5.4. Age-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
- 9.5.5. Type-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
- 9.5.6. Severity-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
- 9.5.7. Treated cases of CRPS in EU4 and the UK
- 9.6. Japan Epidemiology
- 9.6.1. Total Prevalent Cases of CRPS in Japan
- 9.6.2. Total Diagnosed Prevalent cases of CRPS in Japan
- 9.6.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Japan
- 9.6.4. Age-specific Diagnosed Prevalent Cases of CRPS in Japan
- 9.6.5. Type-specific Diagnosed Prevalent Cases of CRPS in Japan
- 9.6.6. Severity-specific Diagnosed Prevalent Cases of CRPS in Japan
- 9.6.7. Treated cases of CRPS in Japan
10. Unmet Needs
11. Appendix
- 11.1. Bibliography
- 11.2. Acronyms and Abbreviations
- 11.3. Report Methodology
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight
List of Tables
- Table 1: Summary of CRPS, Market, Epidemiology, and Key Events (2019-2032)
- Table 2: Comparison between Signs and Symptoms of CRPS Type 1 and 2
- Table 3: Difference between CRPS Types
- Table 4: Common characteristics of CRPS
- Table 5: Stages of CRPS
- Table 6: Possible mechanisms involved in complex regional pain syndrome
- Table 7: Differential Diagnosis
- Table 8: Technical Investigations Helpful to Exclude a Differential Diagnosis
- Table 9: Differential Diagnosis
- Table 10: Levels of evidence
- Table 11: Revised CRPS criteria adopted by the IASP in 2012
- Table 12: Factors (and factor loadings) resulting from principal components factor analysis of diagnostic and associated signs and symptoms of CRPS
- Table 13: Summary of sensitivity and specificity of the clinical and research criteria
- Table 14: Diagnosis of CRPS - Recommendations
- Table 15: Referral - Recommendations
- Table 16: Surgical practice - Diagnostic Recommendations
- Table 17: Diagnosis of CRPS in emergency medicine - Recommendations
- Table 18: The Veldman criteria
- Table 19: Factors (and factor loadings) resulting from factor analysis of CRPS-related signs/symptoms
- Table 20: Japanese CRPS diagnostic criteria for clinical purposes
- Table 21: Pharmacotherapy guide
- Table 22: Management of suspected or confirmed CRPS - Recommendations
- Table 23: Therapeutic approaches
- Table 24: Yellow Flags
- Table 25: Examples of CRPS-specific rehabilitation techniques
- Table 26: Occupational therapy and physiotherapy- Recommendations
- Table 27: Surgical practice - Management Recommendations
- Table 28: Surgery to amputate the CRPS-affected limb - Recommendations
- Table 29: Management and referral of CRPS in emergency medicine - Recommendations
- Table 30: Management of CRPS in pain clinics
- Table 31: Management of CRPS in pain clinics-referral
- Table 32: Management of patients with CRPS and complex needs
- Table 33: Long-term support in CRPS
- Table 34: Total Prevalent Cases of CRPS in the 7MM (2019-2032)
- Table 35: Total Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Table 36: Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Table 37: Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Table 38: Type-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Table 39: Severity-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Table 40: Treated Cases of CRPS in the 7MM (2019-2032)
- Table 41: Total Prevalent Cases of CRPS in the United States (2019-2032)
- Table 42: Total Diagnosed Prevalent cases of CRPS in the United States (2019-2032)
- Table 43: Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Table 44: Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Table 45: Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Table 46: Severity-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Table 47: Total Treated cases of CRPS in the United States (2019-2032)
- Table 48: Total Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Table 49: Total Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Table 50: Gender-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Table 51: Age-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Table 52: Type-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Table 53: Severity-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Table 54: Total Treated Cases of CRPS in EU4 and the UK (2019-2032)
- Table 55: Total Prevalent Cases of CRPS in Japan (2019-2032)
- Table 56: Total Diagnosed Prevalent cases of CRPS in Japan (2019-2032)
- Table 57: Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Table 58: Age-specific Prevalent Cases of CRPS in Japan (2019-2032)
- Table 59: Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Table 60: Severity-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Table 61: Treated cases of CRPS in Japan (2019-2032)
List of Figures
- Figure 1: Epidemiology and Market Methodology
- Figure 2: Understanding of CRPS
- Figure 3: Typical features of a patient with CRPS
- Figure 4: Clinical Manifestations of CRPS and their respective pathophysiological mechanisms
- Figure 5: Model for the development of complex regional pain syndrome (CRPS) from nerve injury
- Figure 6: Speculative model of interacting mechanisms involved in the development of CRPS
- Figure 7: Treatment algorithm
- Figure 8: Four pillars of treatment for CRPS - an integrated interdisciplinary approach
- Figure 9: Pathophysiology and mechanism-based treatment options in CRPS
- Figure 10: CRPS rehabilitation algorithm for occupational therapists and physiotherapists
- Figure 11: Total Prevalent Cases of CRPS in the 7MM (2019-2032)
- Figure 12: Total Diagnosed Prevalent cases of CRPS in the 7MM (2019-2032)
- Figure 13: Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Figure 14: Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Figure 15: Type-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Figure 16: Severity-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
- Figure 17: Treated cases of CRPS in the 7MM (2019-2032)
- Figure 18: Total Prevalent Cases of CRPS in the United States (2019-2032)
- Figure 19: Total Diagnosed Prevalent cases of CRPS in the United States (2019-2032)
- Figure 20: Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Figure 21: Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Figure 22: Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Figure 23: Severity-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
- Figure 24: Treated cases of CRPS in the United States (2019-2032)
- Figure 25: Total Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Figure 26: Total Diagnosed Prevalent cases of CRPS in EU4 and the UK (2019-2032)
- Figure 27: Gender-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Figure 28: Age-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Figure 29: Type-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Figure 30: Severity-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
- Figure 31: Treated cases of CRPS in EU4 and the UK (2019-2032)
- Figure 32: Total Prevalent Cases of CRPS in Japan (2019-2032)
- Figure 33: Total Diagnosed Prevalent cases of CRPS in Japan (2019-2032)
- Figure 34: Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Figure 35: Age-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Figure 36: Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Figure 37: Severity-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
- Figure 38: Treated cases of CRPS in Japan (2019-2032)
